✦ LIBER ✦
471 KRAS, BRAF and PIK3Ca Mutations as Predictors of Outcome From Maintenance Therapy with Bevacizumab with or Without Erlotinib After First Line Combination Therapy for Metastatic Colorectal Cancer: Results of the Phase III ACT Trial NCT00598156 Translational Study
✍ Scribed by Spindler, K.G.; dePont Christensen, R.; Andersen, R.F.; Pallisgaard, N.; Johnson, A.; Jakobsen, A.
- Book ID
- 123564653
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 59 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.